Advertisement
Canada markets open in 4 hours 3 minutes

  • S&P/TSX

    21,714.54
    -297.08 (-1.35%)
     

  • S&P 500

    5,035.69
    -80.48 (-1.57%)
     

  • DOW

    37,815.92
    -570.17 (-1.49%)
     

  • CAD/USD

    0.7261
    0.0000 (-0.00%)
     

  • CRUDE OIL

    80.70
    -1.23 (-1.50%)
     

  • Bitcoin CAD

    79,070.86
    -6,346.70 (-7.43%)
     

  • CMC Crypto 200

    1,235.79
    -103.28 (-7.71%)
     

  • GOLD FUTURES

    2,298.40
    -4.50 (-0.20%)
     

  • RUSSELL 2000

    1,973.91
    -42.12 (-2.09%)
     

  • 10-Yr Bond

    4.6860
    +0.0720 (+1.56%)
     

  • NASDAQ futures

    17,442.75
    -128.50 (-0.73%)
     

  • VOLATILITY

    16.02
    +0.37 (+2.36%)
     

  • FTSE

    8,152.60
    +8.47 (+0.10%)
     

  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     

  • CAD/EUR

    0.6802
    0.0000 (0.00%)
     

UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Business Wire
·1 min read

ROCKVILLE, Md. & EDMONTON, Alberta, April 16, 2024--(BUSINESS WIRE)--NOTE: The new presentation time for Aurinia’s presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conferences is 4:00 to 4:30 PM Eastern Time. This event is presentation only. Webcast Details remain the same.

The updated release reads:

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.

Aurinia management will host one-on-one meetings with investors and will host a presentation on Tuesday, April 16, from 4:00 to 4:30 PM Eastern Time. A live webcast of the session will be available on the investor section of Aurinia’s website, which can be found here.

ADVERTISEMENT

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240416949452/en/

Contacts

Media and Investor Inquiries:
Andrea Christopher
Corporate Communications and Investor Relations, Aurinia
achristopher@auriniapharma.com
ir@auriniapharma.com